AU2020336128A1 - Methods and uses for apelin receptor agonists - Google Patents

Methods and uses for apelin receptor agonists Download PDF

Info

Publication number
AU2020336128A1
AU2020336128A1 AU2020336128A AU2020336128A AU2020336128A1 AU 2020336128 A1 AU2020336128 A1 AU 2020336128A1 AU 2020336128 A AU2020336128 A AU 2020336128A AU 2020336128 A AU2020336128 A AU 2020336128A AU 2020336128 A1 AU2020336128 A1 AU 2020336128A1
Authority
AU
Australia
Prior art keywords
formamido
pyrazol
cyclopentyl
phenyl
dimethoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020336128A
Other languages
English (en)
Inventor
Rangan MAITRA
Sanju Narayanan
Kenneth S. Rehder
Scott P. Runyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International Inc
Original Assignee
RTI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International Inc filed Critical RTI International Inc
Publication of AU2020336128A1 publication Critical patent/AU2020336128A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020336128A 2019-08-29 2020-08-28 Methods and uses for apelin receptor agonists Abandoned AU2020336128A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893661P 2019-08-29 2019-08-29
US62/893,661 2019-08-29
PCT/US2020/048375 WO2021041791A1 (en) 2019-08-29 2020-08-28 Methods and uses for apelin receptor agonists

Publications (1)

Publication Number Publication Date
AU2020336128A1 true AU2020336128A1 (en) 2022-02-24

Family

ID=74686048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020336128A Abandoned AU2020336128A1 (en) 2019-08-29 2020-08-28 Methods and uses for apelin receptor agonists

Country Status (6)

Country Link
EP (1) EP4021447A4 (enExample)
JP (1) JP2022545698A (enExample)
KR (1) KR20220054391A (enExample)
AU (1) AU2020336128A1 (enExample)
CA (1) CA3145074A1 (enExample)
WO (1) WO2021041791A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
JP2024507574A (ja) * 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体
EP4459737A4 (en) 2022-05-02 2025-08-20 Lg Energy Solution Ltd ENERGY STORAGE SYSTEM
WO2024148104A1 (en) * 2023-01-03 2024-07-11 BioAge Labs, Inc. Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gain
WO2025213190A1 (en) * 2024-04-05 2025-10-09 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain
WO2025251084A1 (en) * 2024-05-31 2025-12-04 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US8513244B2 (en) * 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
PE20190806A1 (es) * 2016-10-12 2019-06-10 Res Triangle Inst Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
JPWO2018101398A1 (ja) * 2016-12-01 2019-11-07 宇司 永石 炎症性腸疾患の治療方法およびそれに用いるための医薬組成物

Also Published As

Publication number Publication date
CA3145074A1 (en) 2021-03-04
EP4021447A1 (en) 2022-07-06
EP4021447A4 (en) 2023-10-11
JP2022545698A (ja) 2022-10-28
KR20220054391A (ko) 2022-05-02
WO2021041791A1 (en) 2021-03-04
US20220280483A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
WO2021041791A1 (en) Methods and uses for apelin receptor agonists
US10195213B2 (en) Chemical entities that kill senescent cells for use in treating age-related disease
JP6306609B2 (ja) 医薬組成物
US20090137574A1 (en) Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders
US20090264412A1 (en) Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy
US20120028964A1 (en) Pharmaceutical combination
JP2006522750A (ja) 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
JP2006522744A (ja) グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
US11666582B2 (en) Medicament for treating cough
CN102223884B (zh) 固体药物组合物
CN101677997A (zh) 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
KR20070009746A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와ｐｄｅｖ 억제제의 상승작용 조합물
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
TWI419689B (zh) 用於治療薩羅霍症（Ｓｉａｌｏｒｒｈｏｅａ）之醫藥組合物
JP2005533080A (ja) Ｎｋ−１およびｎｋ−３アンタゴニストによる鬱病および不安症の併用療法
JP2002275097A (ja) うつ病のための多剤併用治療
JP2004521856A (ja) Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
JP2005525309A (ja) 医薬品としての使用のためのＭＴＰインヒビター又はａｐｏＢ分泌インヒビターとフィブレートの組み合わせ
US20180042922A1 (en) Compositions and methods of treating a neurodegenerative disease
US12629352B2 (en) Methods and uses for apelin receptor agonists
CA2872396C (en) Pharmaceutical compositions for direct systemic introduction comprising a proton pump inhibitor
US20170143673A1 (en) Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
EP2340819A1 (en) Compositions comprising venlafaxine and celecoxib in the treatment of pain
US20230190740A1 (en) An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
US20210130362A1 (en) Medical use of compound iii

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application